Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 92 articles: HTML format

Single Articles

September 2026
1. GUNSTER JLB, Tramm T, Machiels M, Demaria S, et al
   Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
   Lancet Oncol. 2026;27:e420-e433.
   PubMed     Abstract available
   
   
   
2. DIXON-DOUGLAS JR, Drubay D, Salgado R, Acs B, et al
   Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
   Lancet Oncol. 2026;27:1181-1192.
   PubMed     Abstract available
   
   
   
3. LARA GONZALEZ LE, Giudici F, Salgado R, Yan H, et al
   Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
   Lancet Oncol. 2026;27:1168-1180.
   PubMed     Abstract available
   
   
   August 2026
4. VELIKOVA G, Russell NS, Williams LJ, Pollock R, et al
   Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
   Lancet Oncol. 2026;27:959-972.
   PubMed     Abstract available
   
   
   July 2026
5. HANNOUN-LEVI JM, Margenthaler JA, Anderson B, Di Micco R, et al
   Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.
   Lancet Oncol. 2026 Jul 29:S1470-2045(26)00177.
   PubMed     Abstract available
   
   
   
6. TURNER NC, Mayer EL, Park YH, Janni W, et al
   Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 tr
   Lancet Oncol. 2026 Jul 13:S1470-2045(26)00287.
   PubMed     Abstract available
   
   
   
7. VALENZA C, Regan MM, Burstein HJ
   Now or later? Switching therapies in metastatic breast cancer.
   Lancet Oncol. 2026 Jul 13:S1470-2045(26)00332.
   PubMed    
   
   
   
8. YAO H, Zhang Q, Li H, Yin Y, et al
   Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
   Lancet Oncol. 2026 Jul 1:S1470-2045(26)00193.
   PubMed     Abstract available
   
   
   
9. FAN Y, Zhang H, Tang S, Toi M, et al
   Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.
   Lancet Oncol. 2026;27:e325-e338.
   PubMed     Abstract available
   
   
   
10. SHAMAI G, Kimmel R, Aran D
    The intermediate-risk gap in AI-based breast cancer stratification - Authors' reply.
    Lancet Oncol. 2026;27:e318.
    PubMed    
    
    
    
11. KOINIS F, Saloustros E, Kotsakis A
    The intermediate-risk gap in AI-based breast cancer stratification.
    Lancet Oncol. 2026;27:e317.
    PubMed    
    
    
    
12. KAIDAR-PERSON O, Weltens CG, Fortpied C, Scheijmans LJEE, et al
    Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
    Lancet Oncol. 2026;27:817-829.
    PubMed     Abstract available
    
    
    
13. MAURITZ AJW, de Munck L, Simons JM, Verloop J, et al
    Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
    Lancet Oncol. 2026;27:808-816.
    PubMed     Abstract available
    
    
    
14. SEEFAT RL, Vliek SB, de Jong VMT, Balduzzi S, et al
    Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026;27:795-807.
    PubMed     Abstract available
    
    
    
15. MITCHELL M
    Customised radiation after neoadjuvant chemotherapy in breast cancer.
    Lancet Oncol. 2026;27:764-765.
    PubMed    
    
    
    June 2026
16. KIRBY AM, Hatton NL, Hansen VN, Thomas M, et al
    Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice.
    Lancet Oncol. 2026;27:751-760.
    PubMed     Abstract available
    
    
    
17. BRUNT AM, Cafferty FH, Kirby AM, Patel J, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a ran
    Lancet Oncol. 2026;27:686-698.
    PubMed     Abstract available
    
    
    May 2026
18. DAS M
    Spain expands breast cancer screening programme.
    Lancet Oncol. 2026 May 29:S1470-2045(26)00276.
    PubMed    
    
    
    
19. NAOUM GE
    Reshaping breast cancer radiotherapy after FAST-Forward.
    Lancet Oncol. 2026 May 14:S1470-2045(26)00192.
    PubMed    
    
    
    
20. PFOB A, Pham TH, de Boniface J, Gentilini OD, et al
    Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.
    Lancet Oncol. 2026;27:604-613.
    PubMed     Abstract available
    
    
    
21. BESHR MS, Fahaid A, Shembesh RH, Valachis A, et al
    CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.
    Lancet Oncol. 2026;27:592-603.
    PubMed     Abstract available
    
    
    
22. WANDER SA, Lloyd MR, Keenan JC, Scott EC, et al
    Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
    Lancet Oncol. 2026;27:580-591.
    PubMed     Abstract available
    
    
    
23. MELLOR D
    Turning breast cancer into art with Cancer Research UK.
    Lancet Oncol. 2026;27:549-550.
    PubMed    
    
    
    
24. PILEHVARI A, You W, Anderson RT, Kimmick G, et al
    Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer.
    Lancet Oncol. 2026;27:529-531.
    PubMed    
    
    
    
25. FAN L, Shao ZM
    AKT-targeted triplet therapy in advanced breast cancer.
    Lancet Oncol. 2026;27:528-529.
    PubMed    
    
    
    April 2026
26. PROWSE J
    European Breast Cancer Conference 2026.
    Lancet Oncol. 2026 Apr 2:S1470-2045(26)00173.
    PubMed    
    
    
    March 2026
27. SHAMAI G, Cohen S, Binenbaum Y, Sabo E, et al
    Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.
    Lancet Oncol. 2026 Mar 11:S1470-2045(25)00727.
    PubMed     Abstract available
    
    
    
28. LIU J, Liu Y, Song E, Li H, et al
    Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China - Authors' reply.
    Lancet Oncol. 2026;27:e126.
    PubMed    
    
    
    
29. QIU Z, Jin N
    Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.
    Lancet Oncol. 2026;27:e125.
    PubMed    
    
    
    
30. 
    Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Oncol. 2026;27:302-326.
    PubMed     Abstract available
    
    
    
31. PARK YH
    Beyond regional boundaries: crucial gaps in global breast cancer burden estimates.
    Lancet Oncol. 2026;27:270-271.
    PubMed    
    
    
    February 2026
32. NADER-MARTA G, Mayer EL
    Towards response-adapted neoadjuvant breast cancer treatment.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00767.
    PubMed    
    
    
    
33. LOUIS FM, van der Voort A, van Ramshorst MS, Daletzakis A, et al
    MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2026 Feb 16:S1470-2045(25)00707.
    PubMed     Abstract available
    
    
    January 2026
34. MONTAGNA G, Alvarado M, Myers S, Mrdutt MM, et al
    Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.
    Lancet Oncol. 2026;27:57-67.
    PubMed     Abstract available
    
    
    December 2025
35. PATODIA S
    San Antonio Breast Cancer Symposium 2025.
    Lancet Oncol. 2025 Dec 18:S1470-2045(25)00753.
    PubMed    
    
    
    
36. PFOB A, Pinker K, Vaz-Luis I, Di Meglio A, et al
    The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus.
    Lancet Oncol. 2025;26:e694-e706.
    PubMed     Abstract available
    
    
    
37. CONFORTI F, Holtschmidt J, Nekljudova V, Sala I, et al
    Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
    Lancet Oncol. 2025;26:1584-1597.
    PubMed     Abstract available
    
    
    
38. YUAN J, Bi XW, Hua X, Huang H, et al
    Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1575-1583.
    PubMed     Abstract available
    
    
    
39. LI H, Liu J, Ouyang Q, Wang S, et al
    Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1563-1574.
    PubMed     Abstract available
    
    
    
40. SIKOV WM
    Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?
    Lancet Oncol. 2025;26:1515-1517.
    PubMed    
    
    
    November 2025
41. BARTSCH R, Marhold M, Garde-Noguera J, Gion M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1467-1478.
    PubMed     Abstract available
    
    
    October 2025
42. SAVAS P, Loi S
    Whole-genome sequencing in breast cancer: is it ready for clinical application?
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00428.
    PubMed    
    
    
    
43. BLACK D, Davies HR, Koh GCC, Chmelova L, et al
    Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00400.
    PubMed     Abstract available
    
    
    
44. BIRRELL SN
    Synthetic progestin use and young-onset breast cancer.
    Lancet Oncol. 2025;26:e516.
    PubMed    
    
    
    July 2025
45. GOURD E
    New test for breast cancer set to transform patient treatment.
    Lancet Oncol. 2025 Jul 24:S1470-2045(25)00461.
    PubMed    
    
    
    
46. VILLACAMPA G, Pascual T, Tarantino P, Cortes J, et al
    HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
    Lancet Oncol. 2025 Jul 14:S1470-2045(25)00276.
    PubMed     Abstract available
    
    
    
47. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
    Lancet Oncol. 2025;26:e332-e333.
    PubMed    
    
    
    
48. O'BRIEN KM, House MG, Goldberg M, Jones ME, et al
    Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group.
    Lancet Oncol. 2025;26:911-923.
    PubMed     Abstract available
    
    
    
49. LEVY C
    Hormonal therapy for young-onset breast cancer: current understanding and lessons.
    Lancet Oncol. 2025;26:824-825.
    PubMed    
    
    
    June 2025
50. SAITO M, Iihara H, Shimokawa M, Udagawa R, et al
    Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Oncol. 2025 Jun 17:S1470-2045(25)00233.
    PubMed     Abstract available
    
    
    
51. KIRBY AM, Finneran L, Griffin CL, Brunt AM, et al
    Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.
    Lancet Oncol. 2025 Jun 11:S1470-2045(25)00194.
    PubMed     Abstract available
    
    
    May 2025
52. HASSAN H, Allen I, Rahman T, Allen S, et al
    Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records.
    Lancet Oncol. 2025 May 7:S1470-2045(25)00156.
    PubMed     Abstract available
    
    
    
53. BLONDEAUX E, Sonnenblick A, Agostinetto E, Bas R, et al
    Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
    Lancet Oncol. 2025 May 7:S1470-2045(25)00152.
    PubMed     Abstract available
    
    
    
54. ESCRIVA-DE-ROMANI S, Cejalvo JM, Alba E, Friedmann J, et al
    Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
    Lancet Oncol. 2025 May 5:S1470-2045(25)00140.
    PubMed     Abstract available
    
    
    
55. JENSEN MB, Torpe E, Teunissen Z, Taarnhoj G, et al
    Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group.
    Lancet Oncol. 2025;26:654-662.
    PubMed     Abstract available
    
    
    
56. KUEMMEL S, Graeser M, Schmid P, Reinisch M, et al
    Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:629-640.
    PubMed     Abstract available
    
    
    
57. GRUBER K
    Monstrosity of Tiny Tumours: an artist's journey through breast cancer.
    Lancet Oncol. 2025;26:558.
    PubMed    
    
    
    March 2025
58. DEVI S
    Projected global rise in breast cancer incidence and mortality by 2050.
    Lancet Oncol. 2025 Mar 6:S1470-2045(25)00136.
    PubMed    
    
    
    
59. ZDENKOWSKI N, Kuper-Hommel MJJ, Niman SM, Francis PA, et al
    Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025;26:367-377.
    PubMed     Abstract available
    
    
    
60. MAGSANOC-ALIKPALA MJK, Ylanan AMD, Rivera-Montales C, Magsanoc JM, et al
    Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines.
    Lancet Oncol. 2025;26:287-289.
    PubMed    
    
    
    
61. GONCALVES A, de Nonneville A
    Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer.
    Lancet Oncol. 2025;26:273-274.
    PubMed    
    
    
    February 2025
62. AHN HK, Kim JY, Lee KH, Kim GM, et al
    Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00006.
    PubMed     Abstract available
    
    
    
63. MUNZONE E, Valenza C
    Tailoring the treatment of premenopausal patients with breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00060.
    PubMed    
    
    
    
64. BONNEFOI H, Lerebours F, Pulido M, Arnedos M, et al
    Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
    Lancet Oncol. 2025 Feb 17:S1470-2045(24)00737.
    PubMed     Abstract available
    
    
    
65. SRIDHAR N, Ueno NT
    Navigating the androgen receptor landscape in triple-negative breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00029.
    PubMed    
    
    
    
66. VENKATESAN P
    Largest trial of AI in breast cancer screening launched.
    Lancet Oncol. 2025 Feb 13:S1470-2045(25)00080.
    PubMed    
    
    
    
67. CASASSUS B
    Law to extend free medical treatment for breast cancer in France.
    Lancet Oncol. 2025 Feb 6:S1470-2045(25)00069.
    PubMed    
    
    
    January 2025
68. LI L
    FNAB samples with the STRAT4 assay for breast cancer diagnosis.
    Lancet Oncol. 2025;26:e9.
    PubMed    
    
    
    
69. NG DL, Van Loon K, Weidler J, Bates M, et al
    FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply.
    Lancet Oncol. 2025;26:e10.
    PubMed    
    
    
    December 2024
70. GRUBER K
    Pesticide exposure and increased risk of breast cancer for women in rural Brazil.
    Lancet Oncol. 2024 Dec 19:S1470-2045(24)00726.
    PubMed    
    
    
    
71. HENRY NL
    Optimising therapy and avoiding overtreatment in breast cancer.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00707.
    PubMed    
    
    
    
72. MEATTINI I, De Santis MC, Visani L, Scorsetti M, et al
    Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00661.
    PubMed     Abstract available
    
    
    
73. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2024;25:e629-e638.
    PubMed     Abstract available
    
    
    November 2024
74. CHEN XC, Jiao DC, Qiao JH, Wang CZ, et al
    De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2024 Nov 26:S1470-2045(24)00581.
    PubMed     Abstract available
    
    
    
75. LUND M, Corn G, Jensen MB, Petersen T, et al
    Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data.
    Lancet Oncol. 2024;25:1496-1506.
    PubMed     Abstract available
    
    
    
76. OLIVEIRA M, Pominchuk D, Nowecki Z, Hamilton E, et al
    Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2024;25:1424-1439.
    PubMed     Abstract available
    
    
    October 2024
77. NG DL, Vuhahula E, Kimambo AH, Ndayisaba MC, et al
    Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study.
    Lancet Oncol. 2024 Oct 3:S1470-2045(24)00456.
    PubMed     Abstract available
    
    
    September 2024
78. OLIVEIRA M, Rugo HS, Howell SJ, Dalenc F, et al
    Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Oncol. 2024;25:1231-1244.
    PubMed     Abstract available
    
    
    
79. KOLBERG HC, Kolberg-Liedtke C
    Who does not benefit from whole-breast radiotherapy and how to find them?
    Lancet Oncol. 2024;25:1110-1111.
    PubMed    
    
    
    
80. DE BONIFACE J, Appelgren M, Szulkin R, Alkner S, et al
    Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    Lancet Oncol. 2024;25:1222-1230.
    PubMed     Abstract available
    
    
    August 2024
81. GOURD E
    Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS.
    Lancet Oncol. 2024 Aug 8:S1470-2045(24)00446.
    PubMed    
    
    
    
82. WILLIAMS LJ, Kunkler IH, Taylor KJ, Dunlop J, et al
    Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2024 Aug 7:S1470-2045(24)00347.
    PubMed     Abstract available
    
    
    
83. BARRIO AV
    Time to abandon axillary lymph node dissection in early-stage breast cancer.
    Lancet Oncol. 2024 Aug 6:S1470-2045(24)00385.
    PubMed    
    
    
    July 2024
84. OFUYA M
    Overcoming barriers to early breast cancer presentation in Nigeria.
    Lancet Oncol. 2024;25:840.
    PubMed    
    
    
    
85. GOURD E
    Olufunmilayo Olopade-preventive oncologist using genetics to fight breast cancer in high-risk populations.
    Lancet Oncol. 2024;25:839.
    PubMed    
    
    
    
86. PELLERIN R
    New Canadian draft breast screening guidelines issued.
    Lancet Oncol. 2024;25:836.
    PubMed    
    
    
    May 2024
87. FEHM T, Cottone F, Dunton K, Andre F, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2024;25:614-625.
    PubMed     Abstract available
    
    
    April 2024
88. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    PubMed     Abstract available
    
    
    
89. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
    Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024;25:e139-e151.
    PubMed     Abstract available
    
    
    
90. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Lancet Oncol. 2024;25:474-487.
    PubMed     Abstract available
    
    
    March 2024
91. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
    Non-surgical ablation for breast cancer: an emerging therapeutic option.
    Lancet Oncol. 2024;25:e114-e125.
    PubMed     Abstract available
    
    
    October 2023
92. MUTTER RW, Giri S, Fruth BF, Remmes NB, et al
    Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Lancet Oncol. 2023;24:1083-1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum